Tag results:
Industry & Policy News
Cell Therapy News
Immusoft Awarded $8M in Funding from the California Institute for Regenerative Medicine for MPS I Clinical Program
[Immusoft] Immusoft announced today that the California Institute for Regenerative Medicine has awarded the company an $8M grant.
Cell Therapy News
Bristol Myers Squibb Announces TRANSCEND CLL 004 Trial of Breyanzi® (Lisocabtagene Maraleucel) Met Primary Endpoint of Complete Response Rate in Patients with Relapsed or...
[Bristol Myers Squibb] Bristol Myers Squibb announced topline results from TRANSCEND CLL 004, a Phase I/II, open-label, single-arm, multicenter study evaluating Breyanzi in adults with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.
Hematopoiesis News
FDA Eases Rules Again for Gay Men Seeking to Donate Blood
[Stat News] The Food and Drug Administration announced draft guidelines that would do away with the current three-month abstinence requirement for donations from men who have sex with men. Instead, potential donors would be screened with a questionnaire that evaluates their individual risks for HIV based on sexual behavior, recent partners, and other factors.
Muscle Cell News
Muscular Dystrophy Association’s Venture Philanthropy Program Announces Investment in Non-Viral Gene Therapy
[Muscular Dystrophy Association] The Muscular Dystrophy Association announced a $650,000 investment in Myosana Therapeutics via its MDA Venture Philanthropy program.
Newsletters
UBC Biotech Spin-Off Raises $75M to Bring Cancer Treatments to Patients
[UBC Faculty of Medicine] Alpha-9 Theranostics, a UBC spin-off company founded by three university researchers, has raised $75 million to develop next-generation radiopharmaceuticals that promise to meaningfully improve treatment for people with cancer.
Human Immunology News
Merck Scraps Keytruda Trial for Prostate Cancer After Dismal Interim Data
[Reuters] Merck & Co Inc. (MRK.N) said it was discontinuing a late-stage trial of its blockbuster immunotherapy Keytruda in some prostate cancer patients after interim data showed it was unlikely to meet the study's main goals; the therapy did not extend survival or help extend the time a patient lives without the disease worsening.